G.P.12.03 Telomere shortening and telomere-associated proteins in Duchenne muscular dystrophy

2007 ◽  
Vol 17 (9-10) ◽  
pp. 840
Author(s):  
G.L. Vita ◽  
M. Aguennouz ◽  
L. Cama ◽  
M. De Pasquale ◽  
N. Lanzano ◽  
...  
2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Dominic Scaglioni ◽  
Francesco Catapano ◽  
Matthew Ellis ◽  
Silvia Torelli ◽  
Darren Chambers ◽  
...  

AbstractDuring the last decade, multiple clinical trials for Duchenne muscular dystrophy (DMD) have focused on the induction of dystrophin expression using different strategies. Many of these trials have reported a clear increase in dystrophin protein following treatment. However, the low levels of the induced dystrophin protein have raised questions on its functionality. In our present study, using an unbiased, high-throughput digital image analysis platform, we assessed markers of regeneration and levels of dystrophin associated protein via immunofluorescent analysis of whole muscle sections in 25 DMD boys who received 48-weeks treatment with exon 53 skipping morpholino antisense oligonucleotide (PMO) golodirsen. We demonstrate that the de novo dystrophin induced by exon skipping with PMO golodirsen is capable of conferring a histological benefit in treated patients with an increase in dystrophin associated proteins at the dystrophin positive regions of the sarcolemma in post-treatment biopsies. Although 48 weeks treatment with golodirsen did not result in a significant change in the levels of fetal/developmental myosins for the entire cohort, there was a significant negative correlation between the amount of dystrophin and levels of regeneration observed in different biopsy samples. Our results provide, for the first time, evidence of functionality of induced dystrophin following successful therapeutic intervention in the human.


2011 ◽  
Vol 32 (12) ◽  
pp. 2190-2197 ◽  
Author(s):  
M’Hammed Aguennouz ◽  
Gian Luca Vita ◽  
Sonia Messina ◽  
Annamaria Cama ◽  
Natalia Lanzano ◽  
...  

1999 ◽  
Vol 147 (3) ◽  
pp. 645-658 ◽  
Author(s):  
Derek J. Blake ◽  
Richard Hawkes ◽  
Matthew A. Benson ◽  
Phillip W. Beesley

Duchenne muscular dystrophy is a fatal muscle disease that is often associated with cognitive impairment. Accordingly, dystrophin is found at the muscle sarcolemma and at postsynaptic sites in neurons. In muscle, dystrophin forms part of a membrane-spanning complex, the dystrophin-associated protein complex (DPC). Whereas the composition of the DPC in muscle is well documented, the existence of a similar complex in brain remains largely unknown. To determine the composition of DPC-like complexes in brain, we have examined the molecular associations and distribution of the dystrobrevins, a widely expressed family of dystrophin-associated proteins, some of which are components of the muscle DPC. β-Dystrobrevin is found in neurons and is highly enriched in postsynaptic densities (PSDs). Furthermore, β-dystrobrevin forms a specific complex with dystrophin and syntrophin. By contrast, α-dystrobrevin-1 is found in perivascular astrocytes and Bergmann glia, and is not PSD-enriched. α-Dystrobrevin-1 is associated with Dp71, utrophin, and syntrophin. In the brains of mice that lack dystrophin and Dp71, the dystrobrevin–syntrophin complexes are still formed, whereas in dystrophin-deficient muscle, the assembly of the DPC is disrupted. Thus, despite the similarity in primary sequence, α- and β-dystrobrevin are differentially distributed in the brain where they form separate DPC-like complexes.


Neurology ◽  
1993 ◽  
Vol 43 (4) ◽  
pp. 795-795 ◽  
Author(s):  
K. Ohlendieck ◽  
K. Matsumura ◽  
V. V. Ionasescu ◽  
J. A. Towbin ◽  
E. P. Bosch ◽  
...  

1994 ◽  
Vol 4 (2) ◽  
pp. 115-120 ◽  
Author(s):  
K MATSUMURA ◽  
F TOME ◽  
H COLLIN ◽  
F LETURCQ ◽  
M JEANPIERRE ◽  
...  

1993 ◽  
Vol 92 (2) ◽  
pp. 866-871 ◽  
Author(s):  
K Matsumura ◽  
F M Tomé ◽  
V Ionasescu ◽  
J M Ervasti ◽  
R D Anderson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document